GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » EV-to-Revenue

Chromocell Therapeutics (Chromocell Therapeutics) EV-to-Revenue : (As of Jun. 22, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Chromocell Therapeutics's enterprise value is $10.11 Mil. Chromocell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Chromocell Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Chromocell Therapeutics's EV-to-Revenue or its related term are showing as below:

CHRO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-22), Chromocell Therapeutics's stock price is $1.37. Chromocell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Chromocell Therapeutics's PS Ratio for today is .


Chromocell Therapeutics EV-to-Revenue Historical Data

The historical data trend for Chromocell Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics EV-to-Revenue Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - - -

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chromocell Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Chromocell Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chromocell Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's EV-to-Revenue falls into.



Chromocell Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Chromocell Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10.111/0
=

Chromocell Therapeutics's current Enterprise Value is $10.11 Mil.
Chromocell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics  (AMEX:CHRO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Chromocell Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.37/0
=

Chromocell Therapeutics's share price for today is $1.37.
Chromocell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics (Chromocell Therapeutics) Headlines